# YOLO26 Training Results ‚Äî APCData Cell Detection

> **Version:** V15 Cytology Pipeline
> **Date:** 2026-01-23
> **Dataset:** APCData (425 images, 6 classes Bethesda)

---

## R√©sum√© Ex√©cutif

| Mod√®le | Epochs | mAP50 | mAP50-95 | Recall NILM | Recall SCC | Status |
|--------|--------|-------|----------|-------------|------------|--------|
| **YOLO26n** | 216 (ES) | **41.4%** | **26.3%** | 84.0% | 62.3% | ‚úÖ Baseline |
| YOLO26s | En cours | ? | ? | ? | ? | üîÑ Training |

*ES = Early Stopping*

---

## Exp√©rience 1: YOLO26n Baseline (100 epochs)

**Date:** 2026-01-22
**Dur√©e:** ~10 minutes

### Configuration

```bash
python scripts/cytology/03_train_yolo26_apcdata.py \
    --model yolo26n.pt \
    --epochs 100 \
    --batch 8 \
    --imgsz 640
```

### R√©sultats

| M√©trique | Valeur |
|----------|--------|
| mAP50 | 30.1% |
| mAP50-95 | 17.6% |
| Precision | 29.9% |
| Recall | 41.7% |

#### Performance par classe

| Classe | Instances | Precision | Recall | mAP50 | mAP50-95 |
|--------|-----------|-----------|--------|-------|----------|
| NILM | 375 | 53.2% | 82.7% | 73.7% | 48.8% |
| ASCUS | 78 | 26.3% | 17.8% | 13.8% | 7.3% |
| ASCH | 42 | 21.4% | 14.3% | 15.3% | 9.3% |
| LSIL | 77 | 24.0% | 31.2% | 20.7% | 11.4% |
| HSIL | 92 | 23.0% | 39.1% | 22.6% | 12.2% |
| SCC | 23 | 31.4% | 65.2% | 34.5% | 16.7% |

### Analyse

- ‚úÖ **NILM** (normal): Bon recall 82.7%
- ‚úÖ **SCC** (cancer): Recall 65.2% malgr√© seulement 23 samples
- ‚ö†Ô∏è Classes interm√©diaires faibles (d√©s√©quilibre de classes)

---

## Exp√©rience 2: YOLO26n Extended (300 epochs avec Early Stopping)

**Date:** 2026-01-23
**Dur√©e:** ~26 minutes (early stopping √† epoch 266)
**Best epoch:** 216

### Configuration

```bash
python scripts/cytology/03_train_yolo26_apcdata.py \
    --model yolo26n.pt \
    --epochs 300 \
    --batch 8 \
    --imgsz 640 \
    --patience 50
```

### R√©sultats Finaux

| M√©trique | Valeur | Œî vs Baseline |
|----------|--------|---------------|
| mAP50 | **41.4%** | +37.5% |
| mAP50-95 | **26.3%** | +49.4% |
| Precision | 40.9% | +36.8% |
| Recall | 44.9% | +7.7% |

#### Performance par classe

| Classe | Instances | Precision | Recall | mAP50 | mAP50-95 |
|--------|-----------|-----------|--------|-------|----------|
| **NILM** | 375 | 63.5% | **84.0%** | **82.4%** | 58.1% |
| ASCUS | 78 | 26.9% | 29.5% | 22.3% | 12.6% |
| ASCH | 42 | 41.4% | 35.7% | 29.6% | 20.0% |
| LSIL | 77 | 30.5% | 28.6% | 27.8% | 15.9% |
| HSIL | 92 | 42.5% | 29.3% | 27.2% | 15.1% |
| **SCC** | 23 | 40.6% | **62.3%** | **59.1%** | 36.2% |

### Courbe d'apprentissage

```
Epoch   | cls_loss | mAP50-95
--------|----------|----------
33      | 2.479    | 14.3%
103     | 1.547    | 21.1%
163     | 1.334    | 24.3%  ‚Üê Peak
216     | 1.177    | 26.3%  ‚Üê Best (saved)
266     | 1.177    | 25.3%  ‚Üê Early Stop
```

### Analyse

**Points positifs:**
- ‚úÖ NILM: 84% recall, 82.4% mAP50 ‚Äî excellent
- ‚úÖ SCC: 62% recall ‚Äî d√©tecte la majorit√© des cancers
- ‚úÖ Convergence stable, early stopping appropri√©
- ‚úÖ Vitesse inference: 1.0ms/image

**Limitations:**
- ‚ö†Ô∏è Classes interm√©diaires (ASCUS, ASCH, LSIL, HSIL): 22-30% mAP50
- ‚ö†Ô∏è D√©s√©quilibre de classes s√©v√®re (NILM: 375 vs SCC: 23)
- ‚ö†Ô∏è Mod√®le nano = capacit√© limit√©e (2.4M params)

### Checkpoints

```
runs/detect/runs/cytology/apcdata_yolo26n_20260123_121505/
‚îú‚îÄ‚îÄ weights/
‚îÇ   ‚îú‚îÄ‚îÄ best.pt   (5.4MB) ‚Üê Best @ epoch 216
‚îÇ   ‚îî‚îÄ‚îÄ last.pt   (5.4MB) ‚Üê Epoch 266
‚îú‚îÄ‚îÄ results.csv
‚îú‚îÄ‚îÄ results.png
‚îî‚îÄ‚îÄ confusion_matrix.png
```

---

## Exp√©rience 3: YOLO26s (En cours)

**Date:** 2026-01-23
**Status:** üîÑ En cours

### Configuration

```bash
python scripts/cytology/03_train_yolo26_apcdata.py \
    --model yolo26s.pt \
    --epochs 300 \
    --batch 4 \
    --imgsz 640 \
    --patience 50
```

### Diff√©rences vs YOLO26n

| Aspect | YOLO26n | YOLO26s |
|--------|---------|---------|
| Param√®tres | 2.4M | ~9M |
| GFLOPs | 5.2 | ~20 |
| Batch size | 8 | 4 (OOM risk) |
| Temps/epoch | ~5s | ~15s (estim√©) |

### R√©sultats attendus

- mAP50: +10-15% vs nano
- Meilleure performance sur classes minoritaires
- Temps total: ~1h (estimation)

---

## Dataset: APCData

### Statistiques

| Split | Images | Cellules |
|-------|--------|----------|
| Train | 343 | ~2,932 |
| Val | 82 | 687 |
| **Total** | **425** | **~3,619** |

### Distribution des classes

| Classe | Train | Val | Total | % |
|--------|-------|-----|-------|---|
| NILM | ~300 | 375 | ~675 | 54.6% |
| ASCUS | ~65 | 78 | ~143 | 11.4% |
| ASCH | ~35 | 42 | ~77 | 6.1% |
| LSIL | ~65 | 77 | ~142 | 11.2% |
| HSIL | ~75 | 92 | ~167 | 13.3% |
| SCC | ~20 | 23 | ~43 | 3.4% |

**D√©s√©quilibre critique:** NILM (54.6%) vs SCC (3.4%) = ratio 16:1

---

## Augmentation (Online via Ultralytics)

```python
# Param√®tres actuels dans 03_train_yolo26_apcdata.py
hsv_h=0.015      # Hue (subtle pour staining)
hsv_s=0.4        # Saturation
hsv_v=0.4        # Value/Brightness
degrees=180      # Rotation compl√®te (cellules orient√©es al√©atoirement)
translate=0.1    # Translation ¬±10%
scale=0.5        # Scale ¬±50%
flipud=0.5       # Flip vertical 50%
fliplr=0.5       # Flip horizontal 50%
mosaic=0.5       # Mosa√Øque (4 images combin√©es)
mixup=0.0        # D√©sactiv√© (pr√©serve int√©grit√© cellulaire)
```

---

## D√©cision Architecturale V15.2 (2026-01-23)

> **Validation Expert (Industrie: Hologic, BD-Techcyte)**
>
> L'architecture propos√©e correspond aux standards industrie pour le screening cervical.

### Analyse des R√©sultats YOLO26

**Constat:** YOLO d√©tecte bien les cellules mais confond les classes interm√©diaires.

| Aspect | Performance | Analyse |
|--------|-------------|---------|
| **D√©tection cellules** | Excellente | NILM 84%, SCC 62% recall |
| **Classification** | Faible sur classes similaires | ASCUS/ASCH/LSIL/HSIL: 28-36% recall |

**Cause:** Les classes Bethesda interm√©diaires partagent des morphologies tr√®s proches.
YOLO n'est pas optimis√© pour cette granularit√© fine.

### Architecture Retenue: Detection-Only + Multi-Head

```
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ                     V15.2 ARCHITECTURE PIPELINE                         ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò

                        Image LBC (2048√ó1532)
                               ‚îÇ
                               ‚ñº
                    ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
                    ‚îÇ  YOLO26 Detection    ‚îÇ  ‚Üê 1 classe: "cell"
                    ‚îÇ  (mAP50 > 85%)       ‚îÇ
                    ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                               ‚îÇ
                    Crops cellules d√©tect√©es
                               ‚îÇ
              ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¥‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
              ‚ñº                                 ‚ñº
    ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê              ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
    ‚îÇ  H-Optimus-0     ‚îÇ              ‚îÇ  Morpho Features ‚îÇ
    ‚îÇ  (1536D frozen)  ‚îÇ              ‚îÇ  (20D computed)  ‚îÇ
    ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò              ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
              ‚îÇ                                 ‚îÇ
              ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                            ‚îÇ
                            ‚ñº
                 ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
                 ‚îÇ  Gated Feature      ‚îÇ
                 ‚îÇ  Fusion (GFF)       ‚îÇ
                 ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                            ‚îÇ
                            ‚ñº
                 ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
                 ‚îÇ  Shared Encoder     ‚îÇ
                 ‚îÇ  (256D latent)      ‚îÇ
                 ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                            ‚îÇ
         ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îº‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
         ‚ñº                  ‚ñº                  ‚ñº
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ  Head 1: Binary ‚îÇ ‚îÇ  Head 2: Sev.   ‚îÇ ‚îÇ  Head 3: Fine   ‚îÇ
‚îÇ  Normal/Abnorm  ‚îÇ ‚îÇ  Low/High Risk  ‚îÇ ‚îÇ  6 Bethesda     ‚îÇ
‚îÇ  (Triage)       ‚îÇ ‚îÇ  (+morpho feat) ‚îÇ ‚îÇ  (Diagnostic)   ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
         ‚îÇ                   ‚îÇ                   ‚îÇ
         ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¥‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                            ‚îÇ
                            ‚ñº
                 ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
                 ‚îÇ  Rejection Layer    ‚îÇ
                 ‚îÇ  (Conformal Pred.)  ‚îÇ
                 ‚îÇ  ‚Üí Manual Review    ‚îÇ
                 ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
```

### Sp√©cification des Heads

| Head | Input | Output | R√¥le Clinique |
|------|-------|--------|---------------|
| **Binary** | latent (256) | Normal/Abnormal | Triage rapide |
| **Severity** | latent (256) + morpho (20) | Low-risk/High-risk | Priorisation |
| **Fine** | latent (256) | 6 classes Bethesda | Diagnostic pr√©cis |
| **Rejection** | latent (256) + uncertainty (3) | Review/OK | Safety net |

### Mapping des Classes

**Binary (Head 1):**
- Normal: NILM
- Abnormal: ASCUS, ASCH, LSIL, HSIL, SCC

**Severity (Head 2):**
- Low-risk: NILM, ASCUS, LSIL
- High-risk: ASCH, HSIL, SCC

### Impl√©mentation

- **Script conversion:** `scripts/cytology/04_convert_to_detection_only.py`
- **Multi-Head model:** `src/cytology/models/cytology_classifier.py` ‚Üí `CytologyMultiHead`
- **Loss combin√©e:** `MultiHeadLoss` (Œª_binary=1.0, Œª_severity=1.5, Œª_fine=1.0)

---

## Prochaines √âtapes

### Court terme
1. ‚è≥ Attendre r√©sultats YOLO26s
2. üìä Comparer nano vs small
3. üîÑ Convertir APCData vers detection-only (1 classe)
4. üéØ Entra√Æner YOLO detection-only

### Moyen terme
1. Entra√Æner CytologyMultiHead sur SIPaKMeD (cellules isol√©es)
2. Int√©grer YOLO detection + MultiHead classifier sur APCData
3. Calibrer Rejection Layer (seuil optimal)
4. √âvaluer m√©triques cliniques (Sensibilit√© Malin > 98%)

### Am√©liorations potentielles YOLO Detection
- [ ] Image size 1024 (plus de d√©tails pour petites cellules)
- [ ] YOLO26m si recall insuffisant
- [ ] Test-Time Augmentation (TTA) pour robustesse

---

## R√©f√©rences

### Checkpoints & Configs
- **Checkpoint YOLO26n:** `runs/cytology/apcdata_yolo26n_*/weights/best.pt`
- **Config dataset (6 classes):** `configs/cytology/apcdata_yolo.yaml`

### Scripts
- **Test YOLO:** `scripts/cytology/01_test_yolo26_apcdata.py`
- **Split train/val:** `scripts/cytology/02_prepare_apcdata_split.py`
- **Training YOLO:** `scripts/cytology/03_train_yolo26_apcdata.py`
- **Convert to detection-only:** `scripts/cytology/04_convert_to_detection_only.py`

### Models
- **Multi-Head Classifier:** `src/cytology/models/cytology_classifier.py` ‚Üí `CytologyMultiHead`
- **GFF Module:** `src/cytology/models/cytology_classifier.py` ‚Üí `GatedFeatureFusion`

### Documentation Externe
- **YOLO26:** https://docs.ultralytics.com/models/yolo26/
- **Bethesda System:** https://www.cancer.gov/publications/dictionaries/cancer-terms/def/bethesda-system
